Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced the appointment of David A.
Hollander, M.D., M.B.A., as Chief Research & Development
Officer, an executive officer position reporting to Vicente Anido,
Jr., Ph.D., Aerie’s Chairman and Chief Executive Officer. Dr.
Hollander will commence his employment at Aerie on November 11,
2019 and will direct the Company’s preclinical and clinical
research and development groups, as well as medical and
professional affairs. He was most recently Chief Medical Officer,
Senior Vice President at Ora, Inc.
Dr. Hollander brings outstanding credentials and an impressive
track record to Aerie. He holds a B.S. in Chemistry from Stanford
University, an M.D. from the University of Pennsylvania School of
Medicine and an M.B.A. from the Wharton School. His post-doctoral
training included an internship in internal medicine at
Cedars-Sinai Medical Center, a residency in ophthalmology at UCSF,
and a fellowship in cornea, external-ocular disease and refractive
surgery at UCLA’s Jules Stein Eye Institute. He began his career on
faculty at Jules Stein and served as Assistant Chief of
Ophthalmology at the Greater Los Angeles VA Medical Center. He then
spent a decade at Allergan where his leadership roles included Head
of EyeCare for Global Medical Affairs, as well as VP and
Therapeutic Area Head of Anterior Segment Clinical Development.
During this time, he was able to continue to see patients and teach
residents in the operating room and clinic as an ophthalmologist.
He is an author on more than 75 peer-reviewed publications, has
given more than 100 presentations nationally and internationally,
and holds multiple patents.
Casey Kopczynski, Aerie’s Chief Scientific Officer, will retain
his focus on innovation strategy, leading the newly formed Science
and Technology Group including Aerie’s ophthalmic
sustained-delivery implant platform, new product opportunities and
acquisitions that expand Aerie’s pipeline, as well as representing
Aerie at global medical and scientific meetings.
“We are very excited to have David Hollander join our executive
team. His extensive clinical and R&D background as well as his
global industry experience will be a significant asset to the
Company as we expand Rhopressa® and Rocklatan® globally as well as
advance our ophthalmology pipeline,” said Vicente Anido, Jr.,
Ph.D., Chairman and Chief Executive Officer at Aerie.
Dr. Hollander added, “Aerie has already demonstrated its ability
to grow into a major ophthalmic pharmaceutical company with the
successful launches of Rhopressa® and Rocklatan®. I look forward to
joining the team and contributing to its future growth.”
In connection with his acceptance as Chief Research &
Development Officer of the Company, Dr. Hollander will receive
awards totaling 110,000 stock options and 25,000 shares of
restricted stock. The stock options will vest over 4 years, with
25% vesting on the first anniversary of the hire date and the
remainder vesting ratably on each of the subsequent 36 monthly
anniversaries of the hire date; the restricted stock will vest over
a period of 4 years in four equal annual installments on each
anniversary of the hire date. This award was made outside of
Aerie’s stockholder-approved equity incentive plan and was approved
by the Company’s independent directors as an inducement material to
Dr. Hollander entering into employment with the Company in reliance
on NASDAQ Listing Rule 5635(c)(4), which requires this public
announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
retinal diseases and other diseases of the eye. Aerie's first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated intraocular pressure in patients with open-angle glaucoma
or ocular hypertension, Rocklatan® (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose
combination of Rhopressa® and the widely-prescribed PGA
(prostaglandin analog) latanoprost, has been approved by the FDA
and is now available in the United States. In clinical trials of
Rocklatan®, the most common adverse reactions were conjunctival
hyperemia, corneal verticillata, instillation site pain, and
conjunctival hemorrhage. More information about Rocklatan®,
including the product label, is available at www.rocklatan.com.
Aerie continues to focus on global expansion and the development of
additional product candidates and technologies in ophthalmology,
including for wet age-related macular degeneration and diabetic
macular edema. More information is available at
www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our expectations
regarding the commercialization and manufacturing of Rhopressa® and
Rocklatan® or any current or future product candidates, including
the timing, cost or other aspects of the commercial launch of
Rhopressa® and Rocklatan® or any current or future product
candidates; our commercialization, marketing, manufacturing and
supply management capabilities and strategies; the success, timing
and cost of our ongoing and anticipated preclinical studies and
clinical trials for Rhopressa® and Rocklatan®, with respect to
regulatory approval outside of the United States or additional
indications, and any current or future product candidates,
including statements regarding the timing of initiation and
completion of the studies and trials; our expectations regarding
the effectiveness of Rhopressa®, Rocklatan® or any current or
future product candidates; the timing of and our ability to
request, obtain and maintain FDA or other regulatory authority
approval of, or other action with respect to, as applicable,
Rhopressa®, Rocklatan® or any current or future product candidates,
including the expected timing of, and timing of regulatory and/or
other review of, filings for, as applicable, Rhopressa®, Rocklatan®
or any current or future product candidates; the potential
advantages of Rhopressa® and Rocklatan® or any current or future
product candidates; our plans to pursue development of additional
product candidates and technologies within and beyond
ophthalmology; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma, including development of our
retina program; our ability to protect our proprietary technology
and enforce our intellectual property rights; and our expectations
regarding strategic operations, including our ability to in-license
or acquire additional ophthalmic products, product candidates or
technologies. In particular, FDA approval of Rhopressa® and
Rocklatan® do not constitute regulatory approval of Rhopressa® and
Rocklatan® in jurisdictions outside the United States and there can
be no assurance that we will receive regulatory approval for
Rhopressa® and Rocklatan® in jurisdictions outside the United
States. By their nature, forward-looking statements involve risks
and uncertainties because they relate to events, competitive
dynamics, industry change and other factors beyond our control, and
depend on regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). Forward-looking statements are not
guarantees of future performance and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contacts
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191030005041/en/
Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024